Published in Arthritis Rheum on February 01, 2005
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med (2005) 2.89
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 2.30
Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol (2007) 1.69
Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med (2008) 1.24
Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J Immunol (2011) 1.24
Developments in the scientific understanding of lupus. Arthritis Res Ther (2008) 1.22
DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo. Arthritis Res Ther (2009) 1.07
Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther (2006) 1.06
Molecular mechanisms of autoimmunity triggered by microbial infection. Arthritis Res Ther (2005) 1.05
Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J Exp Med (2005) 1.02
A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol (2012) 1.01
Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm (2010) 1.01
Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol Ther (2013) 1.00
A suppressive oligodeoxynucleotide inhibits ocular inflammation. Clin Exp Immunol (2009) 0.98
Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm (2010) 0.98
Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology (2007) 0.98
β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation. J Immunol (2013) 0.94
Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol (2008) 0.94
Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Int Immunol (2011) 0.94
Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset. J Immunol (2012) 0.91
Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Am J Pathol (2010) 0.90
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res (2013) 0.89
IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice. J Autoimmun (2014) 0.88
Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas. Cancer Prev Res (Phila) (2011) 0.86
Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. Clin Exp Immunol (2010) 0.84
Treatment with a toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice. Autoimmunity (2010) 0.83
Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses. Expert Opin Ther Targets (2010) 0.83
Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy. J Biomed Biotechnol (2010) 0.82
Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice. Immunology (2010) 0.81
Suppressive oligodeoxynucleotides promote the development of Th17 cells. PLoS One (2013) 0.80
Roles of B Cell-Intrinsic TLR Signals in Systemic Lupus Erythematosus. Int J Mol Sci (2015) 0.79
Mammalian telomeric DNA suppresses endotoxin-induced uveitis. J Biol Chem (2010) 0.78
Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis. Carcinogenesis (2014) 0.77
Suppressive oligodeoxynucleotides promote the generation of regulatory T cells by inhibiting STAT1 phosphorylation. Int Immunopharmacol (2014) 0.77
Engagement of the B cell receptor for antigen differentially affects B cell responses to Toll-like receptor-7 agonists and antagonists in BXSB mice. Clin Exp Immunol (2011) 0.75
Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention. Curr Allergy Asthma Rep (2012) 0.75
Absent in Melanoma 2 proteins in SLE. Clin Immunol (2017) 0.75
Suppressive oligonucleotides inhibit inflammation in a murine model of mechanical ventilator induced lung injury. J Thorac Dis (2016) 0.75
Pre-clinical screening of immunomodulatory compounds using the parent-into-F1 model. Clin Immunol (2011) 0.75
Use of nanoparticles to deliver immunomodulatory oligonucleotides. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.75
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32
Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol (2004) 5.71
Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol (2008) 5.10
Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med (2006) 5.01
Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol (2006) 4.15
Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol (2006) 4.01
The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc Natl Acad Sci U S A (2007) 3.93
Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med (2005) 3.85
Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol (2007) 3.14
A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med (2009) 2.92
Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med (2005) 2.90
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol (2012) 2.48
DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 2.41
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
TLR-based immune adjuvants. Vaccine (2010) 2.10
Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe (2010) 2.03
Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol (2008) 1.86
Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol (2003) 1.84
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med (2012) 1.74
Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci U S A (2012) 1.74
Pathological role of Toll-like receptor signaling in cerebral malaria. Int Immunol (2006) 1.66
Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity (2011) 1.65
The diagnostic utility of exome sequencing in Joubert syndrome and related disorders. J Hum Genet (2012) 1.64
Innate immune response to viral infection. Cytokine (2008) 1.63
Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol (2012) 1.62
IRF-5 and NF-κB p50 co-regulate IFN-β and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells. Eur J Immunol (2013) 1.62
Cutting Edge: Pivotal function of Ubc13 in thymocyte TCR signaling. J Immunol (2006) 1.60
Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol (2013) 1.60
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.59
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 1.58
Identification of FOXP3-negative regulatory T-like (CD4(+)CD25(+)CD127(low)) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clin Immunol (2011) 1.57
DNA containing CpG motifs induces angiogenesis. Proc Natl Acad Sci U S A (2002) 1.55
Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol (2014) 1.53
Henoch-Schonlein purpura presenting duodenal involvement similar to superior mesenteric artery syndrome in a girl. Eur J Pediatr (2006) 1.51
Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A (2008) 1.51
Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron (2014) 1.50
Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol (2009) 1.49
CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol (2002) 1.48
Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol (2002) 1.48
Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol (2014) 1.46
Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med (2010) 1.46
Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. J Control Release (2012) 1.46
Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol (2004) 1.45
Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol (2004) 1.44
DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A (2013) 1.41
Two-step transplantation for primary hyperoxaluria: a winning strategy to prevent progression of systemic oxalosis in early onset renal insufficiency cases. Pediatr Transplant (2014) 1.40
Superior mesenteric artery syndrome: risk factor for duodenal involvement in Henoch-Schönlein purpura. Pediatr Int (2011) 1.39
Transcriptional regulation of the human TLR9 gene. J Immunol (2004) 1.38
TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur J Immunol (2005) 1.36
Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol (2011) 1.31
CXCL16 influences the nature and specificity of CpG-induced immune activation. J Immunol (2006) 1.30
Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med (2002) 1.30
A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol (2011) 1.30
The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells. Proc Natl Acad Sci U S A (2005) 1.30
NLRP4 negatively regulates autophagic processes through an association with beclin1. J Immunol (2011) 1.29
Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol (2005) 1.27
Malaria parasites require TLR9 signaling for immune evasion by activating regulatory T cells. J Immunol (2008) 1.23
CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol (2003) 1.22
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol (2007) 1.20
A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol (2012) 1.18
Effect of suppressive DNA on CpG-induced immune activation. J Immunol (2002) 1.16
Enhanced TLR-mediated NF-IL6 dependent gene expression by Trib1 deficiency. J Exp Med (2007) 1.16
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun (2005) 1.16
Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol (2010) 1.15
Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol (2011) 1.15
Conversion of one-step to two-step self-etch adhesives for improved efficacy and extended application. Am J Dent (2005) 1.15
Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling. J Immunol (2004) 1.15
Manipulation of host innate immune responses by the malaria parasite. Trends Microbiol (2007) 1.14
Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect Immun (2002) 1.13
Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol (2012) 1.12
Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol (2009) 1.12
Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther (2011) 1.12
Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J Immunol (2005) 1.11
Microtensile dentin bond strength of self-etching resins: effect of a hydrophobic layer. Oper Dent (2005) 1.11
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol (2013) 1.10
CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol (2005) 1.08
Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum (2002) 1.08
CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Mol Immunol (2006) 1.07
Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum (2004) 1.06
CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus. J Immunol (2006) 1.06
Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. J Virol (2009) 1.05
Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur J Immunol (2010) 1.04
CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol (2002) 1.04
HNF1B alterations associated with congenital anomalies of the kidney and urinary tract. Pediatr Nephrol (2010) 1.03
CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J Immunol (2005) 1.03